Charles River Laboratories Net Income 2010-2024 | CRL

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Charles River Laboratories annual net income for 2024 was $0.01B, a 97.83% decline from 2023.
Charles River Laboratories annual net income for 2023 was $0.475B, a 2.39% decline from 2022.
Charles River Laboratories annual net income for 2022 was $0.486B, a 24.36% increase from 2021.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Charles River Laboratories annual net income for 2024 was $0.01B, a 97.83% decline from 2023.
Charles River Laboratories annual net income for 2023 was $0.475B, a 2.39% decline from 2022.
Charles River Laboratories annual net income for 2022 was $0.486B, a 24.36% increase from 2021.

Related Stocks
Company Name	Market Cap
Danaher (DHR)	$150.2B
Elevance Health (ELV)	$90.6B
CVS Health (CVS)	$82.1B
Cencora (COR)	$47.2B
DiDi Global (DIDIY)	$23.3B
Natera (NTRA)	$22.2B
ICON (ICLR)	$16.7B
BioMerieux (BMXMF)	$14.1B
Doximity (DOCS)	$14B
Revvity (RVTY)	$14B
Viatris (VTRS)	$13.2B
Solventum (SOLV)	$12.9B
Avantor (AVTR)	$11.9B
CochLear (CHEOY)	$11.3B
Medpace Holdings (MEDP)	$10.5B
EUROFINS SCIENT (ERFSF)	$9.8B
HealthEquity (HQY)	$9.7B
Sonic Healthcare (SKHHY)	$8.7B
Amplifon S.p.A (AMFPF)	$6.2B
Bausch + Lomb (BLCO)	$5.6B
Organon (OGN)	$4B
Sotera Health (SHC)	$3.8B
BrightSpring Health Services (BTSG)	$3.6B
Surgery Partners (SGRY)	$3.3B
Concentras Parent (CON)	$3B
GeneDx Holdings (WGS)	$2.8B
Alignment Healthcare (ALHC)	$2.8B
Teladoc Health (TDOC)	$2.2B
Ardent Health Partners (ARDT)	$2.1B
Progyny (PGNY)	$2B